Vancomycin Injection Now Available in 4 Ready-to-Use Doses
Vanco Ready, a ready-to-use (RTU) vancomycin injection, has been made available by Xellia Pharmaceuticals.
Vanco Ready, a ready-to-use (RTU) vancomycin injection, has been made available by Xellia Pharmaceuticals.
Cost savings could include reductions in respiratory tract infections, antibiotic prescriptions, and sick days.
Research suggests nasopharyngeal microbiota can be valid proxy for lower respiratory tract microbiota.
Advanced diagnostic platforms to identify viruses can help patients with severe lower respiratory tract infections avoid unnecessary diagnostic testing, reduce antibiotic use, and initiate antiviral therapy.
Nasopharyngeal detection and increased abundance of Lactobacillus during acute respiratory infection with respiratory syncytial virus was associated with a lower risk for childhood wheezing illnesses.
Nebulized hypertonic saline may decrease length of hospital stay and improve clinical severity scores in infants with acute bronchiolitis.
For febrile infants, human rhinovirus is common, and detection does not alter risk of concomitant urinary tract infection or invasive bacterial infection.
A gas-capillary column ion mobility spectrometer may be a feasible and noninvasive tool for clinicians to diagnose respiratory tract infections in hospitalized patients.